Clinical Trials Logo

Pancreatic Neoplasms clinical trials

View clinical trials related to Pancreatic Neoplasms.

Filter by:

NCT ID: NCT05485974 Recruiting - Cancer Clinical Trials

A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

Start date: August 1, 2022
Phase: Phase 1
Study type: Interventional

A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recommended Phase II dose of HBI-2438 and characterize its pharmacokinetic profile.

NCT ID: NCT05483075 Recruiting - Pancreatic Cancer Clinical Trials

Feasibility of a Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic Cancer

Start date: November 15, 2022
Phase: N/A
Study type: Interventional

Pilot study evaluating the feasibility of a 2-4 week health care provider guided exercise intervention prior to surgery for pancreatic cancer.

NCT ID: NCT05482451 Recruiting - Effect of Drug Clinical Trials

Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer

Start date: March 1, 2021
Phase: Early Phase 1
Study type: Interventional

This study is to examine the anticancer activity of the combination therapy with all-trans retinoic acid and nivolumab in patients with chemotherapy-refractory advanced or metastatic pancreatic adenocarcinoma.

NCT ID: NCT05481476 Recruiting - Clinical trials for Pancreatic Neoplasms

Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

Start date: September 2023
Phase: Phase 2
Study type: Interventional

This is a single-center, single-arm, open-label, phase 2 clinical study, to explore the efficacy and safety of surufatinib combined with sintilimab and AG in first-line therapy of patients with locally advanced or metastatic pancreatic cancer.

NCT ID: NCT05481463 Recruiting - Clinical trials for Pancreatic Neoplasms

Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

Start date: March 28, 2022
Phase: Phase 2
Study type: Interventional

This is a single-center, single-arm, open-label, phase 2 clinical study, to explore the efficacy and safety of surufatinib combined with TAS-102 in third-line and later-line therapy of patients with advanced pancreatic cancer

NCT ID: NCT05477576 Active, not recruiting - Clinical trials for Neuroendocrine Tumors

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

ACTION-1
Start date: March 24, 2022
Phase: Phase 3
Study type: Interventional

This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2 in subjects with inoperable, advanced, well-differentiated, somatostatin receptor expressing (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following treatment with Lutetium 177-labelled somatostatin analogue (177Lu-SSA) therapy, such as 177Lu-DOTATATE or 177Lu-DOTATOC (177Lu-DOTATATE/TOC), or 177Lu-high affinity [HA]-DOTATATE.

NCT ID: NCT05471401 Withdrawn - Lung Cancer Clinical Trials

GI Organ Tracking Via Balloon Applicators

Start date: April 25, 2023
Phase: N/A
Study type: Interventional

The hypothesis of this study is that an occlusion balloon catheter placed in the stomach via an oral or nasogastric route will be safe and permit tracking of the stomach during radiation therapy.

NCT ID: NCT05470738 Not yet recruiting - Pancreatic Cancer Clinical Trials

PAncreas Borderline and Locally Advanced Snapshot Study

PALASS
Start date: September 15, 2022
Phase:
Study type: Observational [Patient Registry]

The project's objective is to carry out prospectively, in France, for one year, a descriptive registry study in the management of patients with borderline or locally advanced pancreatic adenocarcinoma, and to collect both the patient's demographic characteristics, but also the therapeutic regimens applied, the types of surgeries performed and the outcome of the patients after surgery, and at three months of follow up (preoperative data, complications's post surgery, quality of the resection, etc.)

NCT ID: NCT05465590 Withdrawn - Breast Cancer Clinical Trials

A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer

Start date: December 2022
Phase: Early Phase 1
Study type: Interventional

The study will evaluate the pharmacokinetics (PK) and safety of a single intravenous (IV) dose of 0.3 mg/kg MB1707 in patients with advanced cancers.

NCT ID: NCT05463328 Not yet recruiting - Pancreas Neoplasm Clinical Trials

Open Versus Laparoscopic Assisted Pancreaticoduodenectomy

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

Compare open and laparoscopic assisted pancreaticoduodenectomy regarding intraoprative blood loss, organ injury, completion of planned laparoscopic steps, duration and early post operative course of pain, hem stability, oral feeding, leakage(pancreatic, billary and intestinal). ,bleeding, mortality, lymph nodes and safety margins .